Molecular approaches to the treatment, prophylaxis, and diagnosis of Alzheimer's disease: Tangle formation, amyloid-β, and microglia in Alzheimer's disease

Journal of Pharmacological Sciences

Volumn 118, Issue 3, 2012, Pages 331-337

  Takata, Kazuyuki ^a   Kitamura, Yoshihisa ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Actin; Alzheimer's disease; Amyloid ; Interaction; Microglia; Tau

Indexed keywords

AMYLOID BETA PROTEIN; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; GALANTAMINE; HIGH MOBILITY GROUP B1 PROTEIN; TAU PROTEIN; WISKOTT ALDRICH SYNDROME PROTEIN;

ALZHEIMER DISEASE; BIOACCUMULATION; CELL PHAGOCYTOSIS; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; HUMAN; MICROGLIA; MICROTUBULE ASSEMBLY; MOLECULAR INTERACTION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SENILE PLAQUE; SHORT SURVEY; SYNAPTIC TRANSMISSION;

EID: 84859493385     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.11R10FM     Document Type: Short Survey

References (59)

1. Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature. 1999;399:A23-A31.
2. Neuroinflammation working group. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383-421.
3. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572-580.
4. Moolman DL, Vitolo OV, Vonsattel JP, Shelanski ML. Dendrite and dendritic spine alterations in Alzheimer models. J Neurocytol. 2004;33:377-387. (Pubitemid 39361303)
5. Wiltfang J, Esselmann H, Bibl M, Smirnov A, Otto M, Paul S, et al. Highly conserved and disease-specific patterns of carboxyterminally truncated Aβ peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J Neurochem. 2002;81:481-496. (Pubitemid 34809327)
6. Shoji M. Molecular approaches to the treatment, prophylaxis, and diagnosis of Alzheimer's disease: Clinical molecular and genetic studies on Alzheimer's disease. J Pharmacol Sci. 2012; 118:345-349.
7. Games D, Adams D, Alessandrini R, Barbour R, Borthelette P, Blackwell C, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature. 1995;373:523-527.
8. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99-102. (Pubitemid 26332733)
9. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med. 1998;4:97-100. (Pubitemid 28133087)
10. Mann DM, Esiri MM. The site of the earliest lesions of Alzheimer's disease. N Engl J Med. 1988;318:789-790. (Pubitemid 18090270)
11. Mann DM. Cerebral amyloidosis, ageing and Alzheimer's disease; a contribution from studies on Down's syndrome. Neurobiol Aging. 1989;10:397-399. (Pubitemid 19245424)
12. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353-356. (Pubitemid 34790756)
13. Ihara Y, Nukina N, Miura R, Ogawara M. Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer's disease. J Biochem. 1986;99:1807-1810.
14. Götz J, Ittner LM, Kins S. Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease? J Neurochem. 2006;98:993-1006. (Pubitemid 44127777)
15. Ishiguro K, Omori A, Takamatsu M, Sato K, Arioka M, Uchida T, et al. Phosphorylation sites on tau by tau protein kinase I, a bovine derived kinase generating an epitope of paired helical filaments. Neurosci Lett. 1992;148:202-206. (Pubitemid 23007739)
16. Alonso AD, Grundke-Iqbal I, Barra HS, Iqbal K. Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc Natl Acad Sci U S A. 1997;94:298-303.
17. Noble W, Olm V, Takata K, Casey E, Mary O, Meyerson J, et al. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron. 2003;38:555-565. (Pubitemid 36645031)
18. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001;293:1487-1491. (Pubitemid 32801551)
19. Götz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Aβ42 fibrils. Science. 2001;293:1491-1495. (Pubitemid 32807681)
20. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Triple-transgenic model of Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 2004;43:321-332. (Pubitemid 39061125)
21. Ryan KA, Pimplikar SW. Activation of GSK-3 and phosphorylation of CRMP2 in transgenic mice expressing APP intracellular domain. J Cell Biol. 2005;171:327-335. (Pubitemid 41540024)
22. Terwel D, Muyllaert D, Dewachter I, Borghgraef P, Croes S, Devijver H, et al. Amyloid activates GSK-3β to aggravate neuronal tauopathy in bigenic mice. Am J Pathol. 2008;172: 786-798. (Pubitemid 351354550)
23. Rhein V, Song X, Wiesner A, Ittner LM, Baysang G, Meier F, et al. Amyloid-β and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci U S A. 2009;106:20057-20062.
24. Vossel KA, Zhang K, Brodbeck J, Daub AC, Sharma P, Finkbeiner S, et al. Tau reduction prevents Aβ-induced defects in axonal transport. Science. 2010;330:198.
25. Hosoi T, Ozawa K. Molecular approaches to the treatment, prophylaxis, and diagnosis of Alzheimer's disease: Endoplasmic reticulum stress and immunological stress in pathogenesis of Alzheimer's disease. J Pharmacol Sci. 2012;118:319-324.
26. Kaneko M, Okuma Y, Nomura Y. Molecular approaches to the treatment, prophylaxis, and diagnosis of Alzheimer's disease: Possible involvement of HRD1, a novel molecule related to endoplasmic reticulum stress, in Alzheimer's disease. J Pharmacol Sci. 2012;118:325-330.
27. Costa RO, Ferreiro E, Martins I, Santana I, Cardoso SM, Oliveira CR, et al. Amyloid β-induced ER stress is enhanced under mitochondrial dysfunction conditions. Neurobiol Aging. In press.
28. Miki H, Suetsugu S, Takenawa T. WAVE, a novel WASP-family protein involved in actin reorganization induced by Rac. EMBO J. 1998;17:6932-6941. (Pubitemid 28550287)
29. Fukata Y, Itoh TJ, Kimura T, Ménager C, Nishimura T, Shiromizu T, et al. CRMP-2 binds to tubulin heterodimers to promote microtubule assembly. Nat Cell Biol. 2002;4:583-591.
30. Yoshida H, Watanabe A, Ihara Y. Collapsin response mediator protein-2 is associated with neurofibrillary tangles in Alzheimer's disease. J Biol Chem. 1998;273:9761-9768. (Pubitemid 28183069)
31. Gu Y, Hamajima N, Ihara Y. Neurofibrillary tangle-associated collapsin response mediator protein-2 (CRMP2) is highly phosphorylated on Thr-509, Ser-518, and Ser-522. Biochemistry. 2000;39:4267-4275. (Pubitemid 30212642)
32. Kitamura Y, Tsuchiya D, Takata K, Shibagaki K, Taniguchi T, Smith MA, et al. Possible involvement of Wiskott-Aldrich syndrome protein family in aberrant neuronal sprouting in Alzheimer's disease. Neurosci Lett. 2003;346:149-152. (Pubitemid 36829283)
33. Takata K, Kitamura Y, Nakata Y, Matsuoka Y, Tomimoto H, Taniguchi T, et al. Involvement of WAVE accumulation in Aβ/APP pathology-dependent tangle modification in Alzheimer's disease. Am J Pathol. 2009;175:17-24.
34. Cole AR, Noble W, van Aalten L, Plattner F, Meimaridou R, Hogan D, et al. Collapsin response mediator protein-2 hyperphosphorylation is an early event in Alzheimer's disease progression. J Neurochem. 2007;103:1132-1144. (Pubitemid 47568734)
35. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, et al. Dendritic function of tau mediates amyloid-β toxicity in Alzheimer's disease mouse models. Cell. 2010;142:387-397.
36. Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, et al. Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alz heimer's disease. J Neurosci. 2011;31:700-711.
37. Kakimura J, Kitamura Y, Takata K, Umeki M, Suzuki S, Shibagaki K, et al. Microglial activation and amyloid-β clearance induced by exogenous heat-shock proteins. FASEB J. 2002;16: 601-603. (Pubitemid 44793415)
38. Kitamura Y, Shibagaki K, Takata K, Tsuchiya D, Taniguchi T, Gebicke-Haerter PJ, et al. Involvement of Wiskott-Aldrich syndrome protein family verprolin-homologous protein (WAVE) and Rac1 in the phagocytosis of amyloid-β (1-42) in rat microglia. J Pharmacol Sci. 2003;92:115-123. (Pubitemid 36833457)
39. Njie EG, Boelen E, Stassen FR, Steinbusch HW, Borchelt DR, Streit WJ. Ex vivo cultures of microglia from young and aged rodent brain reveal age-related changes in microglial function. Neurobiol Aging. 2012;33:195.e1-195.e12.
40. Takata K, Kitamura Y, Tsuchiya D, Kawasaki T, Taniguchi T, Shimohama S. High mobility group box protein-1 inhibits microglial Aβ clearance and enhances Aβ neurotoxicity. J Neurosci Res. 2004;78:880-891. (Pubitemid 39657575)
41. Koenigsknecht-Talboo J, Landreth GE. Microglial phagocytosis induced by fibrillar β-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci. 2005;25: 8240-8249. (Pubitemid 41292118)
42. Akiyama H, McGeer PL. Specificity of mechanisms for plaque removal after Aβ immunotherapy for Alzheimer disease. Nat Med. 2004;10:117-118.
43. Kopec KK, Carroll RT. Phagocytosis is regulated by nitric oxide in murine microglia. Nitric Oxide. 2000;4:103-111. (Pubitemid 30318300)
44. Li R, Shen Y, Yang LB, Lue LF, Finch C, Rogers J. Estrogen enhances uptake of amyloid beta-protein by microglia derived from the human cortex. J Neurochem. 2000;75:1447-1454.
45. Wisniewski T, Konietzko U. Amyloid-β immunisation for Alzheimer's disease. Lancet Neurol. 2008;7:805-811.
46. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med. 2003;9: 448-452. (Pubitemid 36460079)
47. Takata K, Hirata-Fukae C, Becker AG, Chishiro S, Gray AJ, Nishitomi K, et al. Deglycosylated anti-amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration. Eur J Neurosci. 2007;26:2458-2468. (Pubitemid 350050431)
48. 1-42 in rat hippocampus in vivo. Neurosci Lett. 2003;344:87-90.
49. Liu Y, Walter S, Stagi M, Cherny D, Letiembre M, Schulz-Schaeffer W, et al. LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide. Brain. 2005;128:1778-1789. (Pubitemid 41373649)
50. Tahara K, Kim HD, Jin JJ, Maxwell JA, Li L, Fukuchi K. Role of toll-like receptor signaling in Aβ uptake and clearance. Brain. 2006;129:3006-3019. (Pubitemid 44684521)
51. Takata K, Kitamura Y, Saeki M, Terada M, Kagitani S, Kitamura R, et al. Galantamine-induced amyloid-β clearance mediated via stimulation of microglial nicotinic acetylcholine receptors. J Biol Chem. 2010;285:40180-40191.
52. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6: 916-919. (Pubitemid 30644751)
53. Takata K, Kitamura Y, Yanagisawa D, Morikawa S, Morita M, Inubushi T, et al. Microglial transplantation increases amyloid-βclearance in Alzheimer model rats. FEBS Lett. 2007;581: 475-478. (Pubitemid 46149623)
54. Hayashi Y, Tomimatsu Y, Suzuki H, Yamada J, Wu Z, Yao H, et al. The intra-arterial injection of microglia protects hippocampal CA1 neurons against global ischemia-induced functional deficits in rats. Neuroscience. 2006;142:87-96. (Pubitemid 44353931)
55. Imai F, Suzuki H, Oda J, Ninomiya T, Ono K, Sano H, et al. Neuroprotective effect of exogenous microglia in global brain ischemia. J Cereb Blood Flow Metab. 2007;27:488-500.
56. Ono M, Saji H. Molecular approaches to the treatment, prophylaxis, and diagnosis of Alzheimer's disease: Novel PET/SPECT imaging probes for diagnosis of Alzheimer's disease. J Pharmacol Sci. 2012;118:338-344.
57. Simard AR, Rivest S. Bone marrow stem cells have the ability to populate the entire central nervous system into fully differentiated parenchymal microglia. FASEB J. 2004;18:998-1000. (Pubitemid 39561504)
58. Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron. 2006;49: 489-502. (Pubitemid 43221886)
59. Takata K, Takada T, Tatsuda H, Tsuruno T, Nishimura K, Shimohama S, et al. Preparation and characterization of microglia-like cells derived from rat, mouse, and human bone marrow cells for therapeutic strategy of Alzheimer's disease. J Addict Res Ther. 2011;S5:001. doi:10.4172/2155-6105.S5-001.